<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04788485</url>
  </required_header>
  <id_info>
    <org_study_id>PH-MII in neonates</org_study_id>
    <nct_id>NCT04788485</nct_id>
  </id_info>
  <brief_title>Evaluation of Smectite Effect As A Food Thickener On Gastroesophageal Reflux Disease In Neonates Using Combined Esophageal Multichannel Intraluminal Impedance</brief_title>
  <official_title>Evaluation of Smectite Effect As A Food Thickener On Gastroesophageal Reflux Disease In Neonates Using Combined Esophageal Multichannel Intraluminal Impedance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      study of diagnosis of GERD in neonates by MII-PH with trial of smectite for treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective clinical trial conducted on 20 preterm neonates &lt; 37 weeks of&#xD;
      gestation, admitted in NICU, maternity hospital, Ain Shams University. They were assessed for&#xD;
      gastroesophageal reflux disease and investigated using ph-MII for detection of reflux&#xD;
      episodes and they were given Smecta 3gm/day for 7 days at least as a food thickener and then&#xD;
      ph-MII repeated to assess the response&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 25, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of smectite as food thickener for treatment of gastroesophgeal reflux in neonates</measure>
    <time_frame>within 7 days</time_frame>
    <description>efficacy of Smectite as a food thickener in treating GERD in neonates using Multichannel intraluminal impedance-pH monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reliability of signs for diagnosis of gastroesophageal reflux in neonates using MII-pH</measure>
    <time_frame>within 24 hours</time_frame>
    <description>determine the reliability of signs such as cardio-respiratory events, apneas and dystonic neck posturing (Sandifer syndrome) in the diagnosis of GERD using Multichannel intraluminal impedance-pH monitoring.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Gastroesophageal Reflux in Neonates</condition>
  <arm_group>
    <arm_group_label>Neonates before adding smectite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neonates will receive diosmectite for treating of gastroesophageal reflux in neonates after MII-ph</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neonates after adding smectite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neonates after they received diosmectite for treating of gastroesophageal reflux in neonates after MII-ph</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diosmectite</intervention_name>
    <description>use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates</description>
    <arm_group_label>Neonates before adding smectite</arm_group_label>
    <arm_group_label>neonates after adding smectite</arm_group_label>
    <other_name>Smecta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Newborns free of any congenital anomalies or inborn errors of metabolism&#xD;
&#xD;
               -  Infants had signs of reflux like:&#xD;
&#xD;
                    1. Typical or atypical crying and/or irritability&#xD;
&#xD;
                    2. Apparent life-threatening event&#xD;
&#xD;
                    3. Poor appetite; weight loss or poor growth (failure to thrive)&#xD;
&#xD;
                    4. Vomiting&#xD;
&#xD;
                    5. Bronchopulmonary dysplasia&#xD;
&#xD;
                    6. Wheezing, stridor&#xD;
&#xD;
                    7. Recurrent pneumonitis&#xD;
&#xD;
                    8. Sandifer syndrome (ie, posturing with opisthotonus or torticollis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Newborns with GIT anomalies as trans-esophageal fistula, hiatus hernia and other GIT&#xD;
             anomalies causing reflux.&#xD;
&#xD;
               -  Patients with Hirshsprung disease or delayed passage of meconium.&#xD;
&#xD;
               -  History of NEC in the baby.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University-Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <zip>11591</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>Hend Fayez Ahmed</investigator_full_name>
    <investigator_title>specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

